RiboBio Named to Hurun's 2024 Global Gazelles Index and Files IPO Prospectus

Hurun Research Institute, the world's largest compiler of startup rankings, released the Hurun Future Unicorns series – "Hurun Global Gazelles Index 2024". Ribo Life Science has been honored with the title of "Hurun Global Gazelle Enterprise" due to its outstanding performance in recent years in the research and development of small nucleic acid drugs and technologies, BD collaborations, and other fields.

Hurun Research Institute has been tracking unicorn companies since 2017 and gazelle companies, the future unicorns, since 2019. This is the fourth release of the "Global Gazelle Companies List" by Hurun Research Institute, aiming to identify high-growth companies founded after 2000 that are most likely to reach a unicorn-level valuation of one billion US dollars within three years. This marks the second time Ribo Life Science has appeared on a related list after being awarded the title of "Hurun Global Future Unicorn" in 2023. It strongly demonstrates the company's continuous breakthroughs and value creation in the small nucleic acid pharmaceuticals field, as well as the industry's high recognition of Suzhou Ribo Life Science Co., Ltd.'s deep cultivation and accumulated strength in the sector.

Ribo Life Science has been focusing on the research and development of small nucleic acid drugs for many years, aiming to develop the best-in-class RNAi therapeutic drugs in the industry. Currently, relying on its self-controlled, fully integrated small nucleic acid drug R&D platform, the company has 8 clinical-stage products, 7 of which are based on its self-developed RIBO-GalSTAR technology.^TMRibo Life Science has made significant progress in the small nucleic acid liver-targeting delivery technology platform, as well as in extrahepatic targeting delivery technologies for tumors, the central nervous system, lungs, kidneys, muscles, and more. At the beginning of 2024, the company achieved breakthrough self-sustaining capabilities through two major collaborations, one with Boehringer Ingelheim and the other with Qilu Pharmaceutical. As the global small nucleic acid industry is on the verge of explosive growth, Ribo Life Science will stay true to its original mission: to develop innovative drugs that address unmet clinical needs and improve human health through cutting-edge nucleic acid therapeutics. The company aims to provide patients with precise, efficient, and long-lasting treatment options as soon as possible.